- Home
- DHT vs KNSA Comparison
DHT vs KNSA Comparison
Compare DHT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHT
- KNSA
- Stock Information
- Founded
- DHT 2005
- KNSA 2015
- Country
- DHT Bermuda
- KNSA United Kingdom
- Employees
- DHT N/A
- KNSA N/A
- Industry
- DHT Marine Transportation
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- DHT Consumer Discretionary
- KNSA Health Care
- Exchange
- DHT Nasdaq
- KNSA Nasdaq
- Market Cap
- DHT 1.6B
- KNSA 1.9B
- IPO Year
- DHT 2005
- KNSA 2018
- Fundamental
- Price
- DHT $11.58
- KNSA $27.36
- Analyst Decision
- DHT Strong Buy
- KNSA Strong Buy
- Analyst Count
- DHT 4
- KNSA 5
- Target Price
- DHT $13.75
- KNSA $38.80
- AVG Volume (30 Days)
- DHT 1.5M
- KNSA 474.9K
- Earning Date
- DHT 05-06-2025
- KNSA 07-22-2025
- Dividend Yield
- DHT 7.00%
- KNSA N/A
- EPS Growth
- DHT 4.76
- KNSA N/A
- EPS
- DHT 1.10
- KNSA N/A
- Revenue
- DHT $563,104,000.00
- KNSA $481,166,000.00
- Revenue This Year
- DHT N/A
- KNSA $37.21
- Revenue Next Year
- DHT $24.11
- KNSA $5.32
- P/E Ratio
- DHT $10.53
- KNSA N/A
- Revenue Growth
- DHT N/A
- KNSA 59.45
- 52 Week Low
- DHT $8.67
- KNSA $17.38
- 52 Week High
- DHT $12.32
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- DHT 57.35
- KNSA 62.48
- Support Level
- DHT $11.19
- KNSA $26.28
- Resistance Level
- DHT $11.89
- KNSA $27.90
- Average True Range (ATR)
- DHT 0.26
- KNSA 0.99
- MACD
- DHT -0.03
- KNSA -0.07
- Stochastic Oscillator
- DHT 60.62
- KNSA 82.30
About DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. It is an independent crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. It generates revenues from time charter and spot market operations. Its fleets consist of very large crude carriers known as VLCCs that range in size from 270,000 to 320,000 deadweight tons. Geographically, DHT operates in Monaco, Oslo, Norway, and Singapore. The company generates the majority of its revenue from the shipping revenues.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.